Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · IEX Real-Time Price · USD
13.28
-0.66 (-4.73%)
At close: May 1, 2024, 4:00 PM
13.67
+0.39 (2.94%)
After-hours: May 1, 2024, 6:15 PM EDT
Sage Therapeutics Revenue
Sage Therapeutics had revenue of $91.06M in the twelve months ending March 31, 2024, with 868.87% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $7.90M with 139.89% year-over-year growth. In the year 2023, Sage Therapeutics had annual revenue of $86.46M with 1,024.84% growth.
Revenue (ttm)
$91.06M
Revenue Growth
+868.87%
P/S Ratio
8.78
Revenue / Employee
$186,990
Employees
487
Market Cap
799.22M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 86.46M | 78.77M | 1,024.84% |
Dec 31, 2022 | 7.69M | 1.38M | 21.85% |
Dec 31, 2021 | 6.31M | -1.11B | -99.43% |
Dec 31, 2020 | 1.11B | 1.11B | 16,123.06% |
Dec 31, 2019 | 6.87M | -83.41M | -92.39% |
Dec 31, 2018 | 90.27M | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Avanos Medical | 673.30M |
Artivion | 354.00M |
Definitive Healthcare | 251.42M |
Tango Therapeutics | 36.53M |
Mobile-health Network Solutions | 7.87M |
Viridian Therapeutics | 314.00K |
ARS Pharmaceuticals | 30.00K |
SAGE News
- 3 days ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGE - PRNewsWire
- 6 days ago - INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire
- 6 days ago - Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress - Business Wire
- 14 days ago - Sage Therapeutics' stock plunges as Parkinson's drug trial disappoints - Market Watch
- 14 days ago - Sage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage study - Reuters
- 14 days ago - Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease - Business Wire
- 20 days ago - Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 - Business Wire
- 2 months ago - Sage Therapeutics to Present at Upcoming March Investor Conferences - Business Wire